52 studies found for:    "Genital Diseases, Female" | Japan
Show Display Options
Rank Status Study
1 Completed A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
Condition: Endometriosis
Interventions: Drug: ASP1707;   Drug: Placebo;   Drug: Leuprorelin acetate
2 Completed Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
Condition: Endometriosis
Interventions: Drug: EE20/DRSP(BAY86-5300);   Drug: Placebo;   Drug: Dienogest
3 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
4 Completed Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
5 Completed A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
6 Completed
Has Results
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Condition: Pelvic Inflammatory Disease
Intervention: Drug: Azithromycin
7 Completed Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
8 Unknown  Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
Condition: Uterine Cervical Neoplasms
Interventions: Drug: chemotherapy: Paclitaxel/Cisplatin;   Drug: chemotherapy: Paclitaxel/Carboplatin
9 Recruiting Bay98-7196, Dose Finding / POC Study
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: Levonorgestrel;   Drug: Anastrozole + Levonorgestrel (BAY 98-7196);   Drug: Lupron / Leuprolide acetate
10 Completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
11 Recruiting CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Human Papillomavirus Infection;   Stage 0 Cervical Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
12 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
13 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
14 Active, not recruiting
Has Results
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Neoplasms, Ovarian
Interventions: Drug: Pazopanib;   Drug: Placebo
15 Unknown  Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
16 Active, not recruiting TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: Paclitaxel;   Drug: AMG 386 Placebo;   Drug: Carboplatin
17 Recruiting Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
18 Completed
Has Results
The Study Of Fluconazole For Vulvovaginal Candidiasis
Condition: Vulvovaginal Candidiasis
Intervention: Drug: Fluconazole
19 Completed
Has Results
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
20 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years